PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Green light for AbbVie’s Crohn’s disease therapy Rinvoq

AbbVie has revealed that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its therapy, Rinvoq.

Also known as upadacitinib, the drug is a janus kinase (JAK) inhibitor and concerns the treatment of adult patients with moderately to severely active Crohn’s disease (CD). The patients involved would also have had a lost response, inadequate response, or were intolerant to either a biological agent or conventional therapy.

The positive decision from the MHRA was supported by results from three phases 3 clinical trials. These include two induction studies – U-EXCEED & U-EXCEL – and one maintenance study, U-ENDURE. Most significantly, more patients treated with upadacitinib achieved the target endpoints of endoscopic response and clinical remission.

In addition, more patients receiving upadacitinib 45mg once daily at week 12 in the induction studies, or 15mg and 30mg once daily at 52 weeks, during the maintenance research achieved the secondary endpoint of corticosteroid-free clinical remission per stool frequency/abdominal pain (SF/AP) compared to placebo.

Belinda Byrne, medical director at AbbVie UK, was optimistic about the news: “We are proud to be using our two decades of experience in gastroenterology in our commitment to helping better the lives of people with Crohn’s disease. We are pleased that upadacitinib can now be used to treat more people with inflammatory bowel disease.”

Professor James Lindsay, a consultant gastroenterologist at the Royal London Hospital Barts Health NHS Trust, explained: “There have been limited new treatment options approved for Crohn’s disease in recent years and many people struggle to stay in remission, demonstrating a clear unmet need.”

He added: “We’ve seen in clinical trials that upadacitinib has the potential to help people gain control of their disease and, with this MHRA approval, we now have an approved advanced treatment option in a new class of therapy that can be taken as a once-daily pill.”

The worldwide impact of CD is still growing and, as a long-term, debilitating disease the search for a cure is ongoing. The condition is also associated with progressive damage to the digestive system, which can often lead to surgery.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026